Ticagrelor Use in Patients at Risk of Intracranial Hemorrhage

Risk Assessment and Contraindications

• The American Heart Association and American College of Cardiology recommend that ticagrelor should be avoided in patients with a history of intracranial hemorrhage due to FDA boxed warnings and increased bleeding risk, particularly when combined with aspirin 1, 2, 3
• Ticagrelor is absolutely contraindicated in patients with active bleeding or a history of intracranial hemorrhage as specified in the FDA boxed warning 4
• Patients with prior stroke or transient ischemic attack (TIA) represent a high-risk group for intracranial bleeding when receiving dual antiplatelet therapy 3, 5

Mechanism of Action and Bleeding Risk

• Ticagrelor is a direct and reversible P2Y12 receptor antagonist with more rapid functional recovery of platelets compared to clopidogrel 2, 4
• Dual antiplatelet therapy with aspirin and P2Y12 inhibitors (including ticagrelor) has been associated with increased risk of intracranial hemorrhage in multiple clinical trials 3, 4

Dosing Considerations to Minimize Risk

• When ticagrelor is used, the aspirin maintenance dose should be limited to ≤100 mg daily, as higher doses both decrease effectiveness and increase bleeding risk 4, 6
• For patients requiring surgery, ticagrelor should be discontinued at least 5 days before any procedure to reduce bleeding risk 7, 8

Clinical Evidence on Intracranial Bleeding with Ticagrelor

• The PLATO trial showed that ticagrelor had similar rates of major bleeding compared to clopidogrel, but specific data on intracranial hemorrhage in high-risk patients was limited 6

Recommendations for Clinical Practice

• For patients requiring antiplatelet therapy who have risk factors for intracranial bleeding, the American College of Cardiology recommends carefully weighing the increased risk of intracranial bleeding against potential cardiovascular benefits 3, 4
• Consider alternative antiplatelet strategies in patients with prior stroke or TIA, as recommended by the American Heart Association 5, 6

Special Considerations

• Ticagrelor's twice-daily dosing regimen may pose adherence challenges, which could lead to fluctuating platelet inhibition and potentially increased risk, according to the American College of Cardiology 2, 4
• The risk-benefit assessment should be particularly careful in elderly patients, those with prior falls, or patients with other risk factors for intracranial bleeding, as recommended by the American Heart Association 3, 5